查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951951

幹細胞製造市場分析及預測（至2035年）：類型、產品類型、服務、技術、應用、最終用戶、製程、階段

Stem Cell Manufacturing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage
出版日期: | 出版商: Global Insight Services | 英文 303 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計幹細胞生產市場規模將從2024年的139億美元成長到2034年的342億美元，複合年成長率約為10.3%。幹細胞生產市場涵蓋用於治療、研究和藥物開發的幹細胞的生產和擴增。該市場包括先進的生物製程技術、可擴展的培養系統以及確保細胞活力和效力的品管措施。對再生醫學和個人化療法的需求不斷成長，推動了市場發展，而自動化和生物反應器設計的創新則提高了生產效率和擴充性。

幹細胞生產市場正經歷強勁成長，這主要得益於再生醫學的進步和治療應用的不斷拓展。在細胞治療生產領域，這一成長尤為顯著，主要受異體和自體幹細胞療法需求的推動。其中，異體幹細胞療法細分市場成長最為迅猛，這主要歸功於其擴充性和大規模生產的潛力；其次是提供個人化治療方案、改善患者預後的異體幹細胞療法。生物製劑生產設備領域也表現強勁，生物反應器和細胞培養系統在高效幹細胞生產中發揮關鍵作用。第二大成長領域－耗材細分市場（包括培養基和試劑）預計將顯著成長，這主要得益於幹細胞培養對高品質原料的持續需求。對自動化和流程標準化的高度重視正在推動創新，確保產品品質的穩定性並降低生產成本。這些趨勢為投資和策略合作提供了有利機會。

市場區隔
類型 成體幹細胞、胚胎幹細胞、誘導性多功能幹細胞
產品 細胞株、設備、耗材、培養基及試劑
服務 細胞庫、細胞鑑定、細胞分化、細胞擴增、冷凍保存、品管
科技 3D細胞培養、生物反應器、細胞分離、細胞分選、冷凍保存
應用領域 再生醫學、藥物發現、毒性測試、組織工程、臨床研究
最終用戶 生技公司、製藥公司、研究機構、醫院、學術機構
過程 上游工程、下游製程、細胞增殖、細胞收穫
步 研究與開發、臨床試驗和商業化生產

幹細胞製造市場正面臨不斷變化的格局，其特點是策略性定價和創新產品不斷湧現。各公司正利用先進技術提高生產效率，並最佳化定價策略以保持競爭力。專注於治療應用和再生醫學的新型幹細胞產品正在推動市場動態。這一趨勢凸顯了對個人化醫療日益成長的需求，增強了市場的吸引力，並推動了強勁的成長前景。幹細胞製造領域的競爭異常激烈，主要企業正尋求透過技術創新和策略聯盟來鞏固主導。法規結構，尤其是在北美和歐洲，在塑造市場標準和影響競​​爭格局方面發揮關鍵作用。這些法規確保了產品的安全性和有效性，並促進了創新和合規性。該市場的特點是高度重視研發活動，並投入大量資金來改善生產流程和擴展產品系列。這種競爭格局表明，在監管影響和技術進步的驅動下，該市場已做好持續成長的準備。

主要趨勢和促進因素：

幹細胞生產市場正經歷強勁成長，這主要得益於再生醫學和個人化療法的進步。關鍵趨勢包括將自動化和人工智慧融入生產流程，從而提高精度和效率。細胞療法因其治療慢性疾病的潛力而日益受到關注，這是推動市場發展的關鍵因素。此外，探索幹細胞應用的臨床試驗不斷擴展，也加速了市場的發展動能。監管機構的支持和政府對幹細胞研究的資助對於推動市場擴張至關重要。這種支持促進了創新，並支持了新型治療方法的開發。學術機構和產業參與者之間日益密切的合作正在刺激研發活動，並加速幹細胞產品的商業化進程。此外，對生產流程中品管和標準化的日益重視，確保了產品的安全性和有效性，進一步增強了市場信心。新興市場醫療基礎設施的不斷改進和人們對幹細胞療法的認知不斷提高，為市場帶來了大量機會。投資於策略合作和技術創新的公司將更有利於獲得市場佔有率。隨著產業的不斷發展，專注於開發擴充性、經濟高效的生產解決方案對於滿足不斷成長的需求至關重要。幹細胞製造市場預計將在創新和治療應用不斷擴展的推動下持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 成體幹細胞
    • 胚胎幹細胞
    • 誘導性多功能幹細胞
  • 市場規模及預測：依產品分類
    • 細胞株
    • 裝置
    • 消耗品
    • 培養基
    • 試劑
  • 市場規模及預測：依服務分類
    • 細胞庫
    • 細胞表徵
    • 細胞分化
    • 細胞增殖
    • 冷凍保存
    • 品管
  • 市場規模及預測：依技術分類
    • 3D細胞培養
    • 生物反應器
    • 細胞分離
    • 細胞分級分離
    • 冷凍保存
  • 市場規模及預測：依應用領域分類
    • 再生醫學
    • 藥物發現
    • 毒理學研究
    • 組織工程
    • 臨床研究
  • 市場規模及預測：依最終用戶分類
    • 生技公司
    • 製藥公司
    • 研究所
    • 醫院
    • 學術機構
  • 市場規模及預測：依製程分類
    • 上游工程
    • 下游工藝
    • 細胞增殖
    • 細胞收集
  • 市場規模及預測：依階段分類
    • 研究與開發
    • 臨床試驗
    • 商業生產

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Lonza
  • Thermo Fisher Scientific
  • STEMCELL Technologies
  • Cell Genix
  • Cytiva
  • Promo Cell
  • Bio-Techne
  • Takara Bio
  • Miltenyi Biotec
  • Pluristem Therapeutics
  • Fujifilm Cellular Dynamics
  • Astellas Institute for Regenerative Medicine
  • Re Neuron Group
  • Brain Storm Cell Therapeutics
  • Mesoblast
  • Gamida Cell
  • Organogenesis
  • Vericel Corporation
  • Athersys
  • Cellectis

第9章：關於我們

簡介目錄
Product Code: GIS20577

Stem Cell Manufacturing Market is anticipated to expand from $13.9 billion in 2024 to $34.2 billion by 2034, growing at a CAGR of approximately 10.3%. The Stem Cell Manufacturing Market encompasses the production and expansion of stem cells for therapeutic applications, research, and drug development. This market includes advanced bioprocessing technologies, scalable culture systems, and quality control measures to ensure cell viability and potency. Rising demand for regenerative medicine and personalized therapies is propelling growth, with innovations in automation and bioreactor design enhancing production efficiency and scalability.

The Stem Cell Manufacturing Market is experiencing robust growth, fueled by advancements in regenerative medicine and increasing therapeutic applications. The cell therapy manufacturing segment stands out, driven by the demand for allogeneic and autologous stem cell therapies. Within this segment, the allogeneic therapies sub-segment is the top performer, attributed to its scalability and potential for mass production. Autologous therapies follow, offering personalized treatment options that enhance patient outcomes. The biologics manufacturing equipment segment also exhibits strong performance, with bioreactors and cell culture systems playing pivotal roles in efficient stem cell production. As the second highest-performing segment, the consumables sub-segment, including media and reagents, is expected to grow significantly due to the continuous need for high-quality inputs in stem cell cultures. The emphasis on automation and process standardization is driving innovation, ensuring consistent product quality and reducing manufacturing costs. These trends indicate lucrative opportunities for investment and strategic partnerships.

Market Segmentation
TypeAdult Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem Cells
ProductCell Lines, Instruments, Consumables, Culture Media, Reagents
ServicesCell Banking, Cell Characterization, Cell Differentiation, Cell Expansion, Cryopreservation, Quality Control
Technology3D Cell Culture, Bioreactors, Cell Isolation, Cell Sorting, Cryopreservation
ApplicationRegenerative Medicine, Drug Discovery, Toxicology Studies, Tissue Engineering, Clinical Research
End UserBiotechnology Companies, Pharmaceutical Companies, Research Institutes, Hospitals, Academic Institutions
ProcessUpstream Processing, Downstream Processing, Cell Expansion, Cell Harvesting
StageResearch and Development, Clinical Trials, Commercial Production

The Stem Cell Manufacturing Market is witnessing an evolving landscape marked by strategic pricing and innovative product launches. Companies are leveraging advanced technologies to enhance production efficiency, thereby optimizing pricing strategies to remain competitive. The introduction of novel stem cell products is driving market dynamics, with a focus on therapeutic applications and regenerative medicine. This trend underscores the growing demand for personalized medicine, enhancing market attractiveness and fostering robust growth prospects. Competition within the stem cell manufacturing sector is intense, with key players striving for dominance through technological advancements and strategic partnerships. Regulatory frameworks, particularly in North America and Europe, play a pivotal role in shaping market standards and influencing the competitive landscape. These regulations ensure product safety and efficacy, driving innovation and compliance. The market is characterized by a strong focus on R&D activities, with substantial investments directed towards improving manufacturing processes and expanding product portfolios. This competitive benchmarking reveals a market poised for sustained growth, driven by regulatory influences and technological progress.

Geographical Overview:

The stem cell manufacturing market is witnessing robust growth across diverse regions, each exhibiting unique trends. North America dominates, propelled by cutting-edge research and substantial funding in regenerative medicine. The region's advanced healthcare infrastructure and strong regulatory support bolster market expansion. Europe follows, with significant investments in stem cell research and a growing focus on personalized medicine. The region's commitment to innovative healthcare solutions enhances its market position. In Asia Pacific, rapid technological advancements and increasing government support drive market growth. Countries like China and Japan are emerging as key players, investing heavily in stem cell research and manufacturing capabilities. Latin America and the Middle East & Africa present burgeoning opportunities. In Latin America, rising healthcare investments and growing awareness of stem cell therapies contribute to market expansion. The Middle East & Africa are recognizing the potential of stem cell technologies in addressing prevalent health challenges, thereby fostering market growth and innovation.

Global tariffs and geopolitical tensions are significantly influencing the Stem Cell Manufacturing Market. Japan and South Korea are enhancing domestic capabilities to mitigate reliance on foreign imports, particularly from the US and China. China's strategic pivot towards self-reliance is evident in its substantial investments in biotech infrastructure, while Taiwan leverages its expertise in precision manufacturing to maintain a competitive edge. The parent market is experiencing robust growth, driven by advancements in regenerative medicine and increasing demand for personalized therapies. By 2035, the market is poised for substantial expansion, underpinned by collaborative regional partnerships and innovation. Middle East conflicts exert pressure on global supply chains, potentially elevating energy costs, which could indirectly affect manufacturing expenses and timelines across these Asian markets.

Key Trends and Drivers:

The Stem Cell Manufacturing Market is experiencing robust growth, propelled by advancements in regenerative medicine and personalized therapies. Key trends include the integration of automation and artificial intelligence in manufacturing processes, enhancing precision and efficiency. The increasing demand for cell-based therapies, driven by their potential to treat chronic diseases, is a significant market driver. Moreover, the expansion of clinical trials exploring stem cell applications is fueling market momentum. Regulatory support and government funding for stem cell research are pivotal in driving market expansion. This support is encouraging innovation and facilitating the development of novel therapies. The rise of collaborations between academic institutions and industry players is fostering research and development activities, catalyzing the commercialization of stem cell products. Additionally, the growing focus on quality control and standardization in manufacturing processes is ensuring product safety and efficacy, further boosting market confidence. Opportunities abound in emerging markets where healthcare infrastructure is improving, and awareness of stem cell therapies is increasing. Companies that invest in strategic partnerships and technological advancements are well-positioned to capture market share. As the industry evolves, the focus on developing scalable and cost-effective manufacturing solutions will be crucial to meet the rising demand. The Stem Cell Manufacturing Market is poised for sustained growth, driven by innovation and expanding therapeutic applications.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Adult Stem Cells
    • 4.1.2 Embryonic Stem Cells
    • 4.1.3 Induced Pluripotent Stem Cells
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cell Lines
    • 4.2.2 Instruments
    • 4.2.3 Consumables
    • 4.2.4 Culture Media
    • 4.2.5 Reagents
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Cell Banking
    • 4.3.2 Cell Characterization
    • 4.3.3 Cell Differentiation
    • 4.3.4 Cell Expansion
    • 4.3.5 Cryopreservation
    • 4.3.6 Quality Control
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 3D Cell Culture
    • 4.4.2 Bioreactors
    • 4.4.3 Cell Isolation
    • 4.4.4 Cell Sorting
    • 4.4.5 Cryopreservation
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Regenerative Medicine
    • 4.5.2 Drug Discovery
    • 4.5.3 Toxicology Studies
    • 4.5.4 Tissue Engineering
    • 4.5.5 Clinical Research
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Hospitals
    • 4.6.5 Academic Institutions
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Upstream Processing
    • 4.7.2 Downstream Processing
    • 4.7.3 Cell Expansion
    • 4.7.4 Cell Harvesting
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Research and Development
    • 4.8.2 Clinical Trials
    • 4.8.3 Commercial Production

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Lonza
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Thermo Fisher Scientific
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 STEMCELL Technologies
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cell Genix
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Cytiva
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Promo Cell
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Bio- Techne
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Takara Bio
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Miltenyi Biotec
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Pluristem Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Fujifilm Cellular Dynamics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Astellas Institute for Regenerative Medicine
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Re Neuron Group
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Brain Storm Cell Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Mesoblast
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Gamida Cell
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Organogenesis
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Vericel Corporation
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Athersys
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Cellectis
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us